The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B

Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Hee Man Kim, Jung Min Lee, Chae Yoon Chon, Young Nyun Park, Kwang Hyub Han, Jun Yong Park

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background/Aims: Recently, several studies have indicated that liver stiffness measurement (LSM) using FibroScan® accurately predicts liver fibrosis. This study investigated the impact of steatosis on LSM in patients with chronic hepatitis B (CHB). Methodology: The study prospectively enrolled 162 patients (106 men and 56 women) with CHB who underwent both a liver biopsy and LSM between January 2005 and June 2008. We examined the overall univariate correlation between steatosis and LSM value and also performed a multivariate regression analysis to identify independent variables influencing LSM values. Results: The mean age of the patients was 44.4 years and the mean body mass index was 23.3±2.8kg/m2. The fibrosis stage ranged from F1 to F4 in 16 patients (9.9%), 37 (22.8%), 17 (10.5%) and 92 (56.8%), respectively. Steatosis was S0 in 128 patients (79.0%), Sl in 28 (17.3%), S2 in 6 (3.7%) and S3 in none. No overall significant correlation was noted between LSM value and steatosis (r=0.023, p=0.770). In the multivariate linear regression analysis, only fibrosis stage showed statistical significance (r=0.268, p<0.001), while steatosis did not (r=0.013, p=0.841). Conclusions: Our findings suggest that mild to moderate steatosis does not have a significant impact on LSM values in patients with CHB.

Original languageEnglish
Pages (from-to)832-838
Number of pages7
Issue number101
Publication statusPublished - 2010 Jul

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B'. Together they form a unique fingerprint.

Cite this